Fortis Healthcare Ltd NSE  /  BSE

Healthcare, Large Cap

19 Jul 2019 | 04:14 PM

0.20 (0.15%)

Independent Research


We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts positive since 26-Mar-2019

    Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 26-Mar-2019 at a price of 136.30.

  • Valuation Rating

    Moderately undervalued

    Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.

  • MT Tech Trend

    Trend neutral but previously positive (since 12-Mar-2019)

    The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 12-Mar-2019), the stock traded above its moving average. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 133.900.

  • 4W REL Performance

    Under pressure (vs. SENSEX30)

    The four week relative underperformance versus SENSEX30 is -5.320.

Risk parameters

  • Risk Zone


    The stock has been on the moderate-sensitivity level since 08-Feb-2019.

  • Bear Market

    Average sensitivity to market corrections

    On average, the stock is likely to decline with the index.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 252%.

  • Beta

    54 Low sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 54%.

  • Correlation

    0.24 Weak correlation to SENSEX30

    Stock movements are strongly independent of index variations.

  • Value at Risk

    Rs.20.39 The medium term value at risk is estimated at 20.39 or 0.14958%

    The value at risk is estimated at 20.39. The risk is therefore 0.14958%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    357.06 Current year to 2021 annualized estimate

    The annualized growth estimate is for the current year to 2021.

  • P/E Ratio

    22.65 Estimated PE for 2021

    The estimated PE is for the year 2021.

  • G/PE Ratio

    15.77 High discount to expected growth due to base effect

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).

  • Dividend Yield

    0.01% Dividend is largely covered by profits

    The twelve month estimated dividend yield represents 0.311% of earnings forecasts.

  • Global Evaluation


    The stock is classified in the neutral zone since 15-Mar-2019.